IP Library Granted Patent US 10,603,294
Granted Patent B2
US 10,603,294 · App. 16/248,422 · Granted Mar 31, 2020

Compounds for use in treatment of mucositis

Inventors: Richard W. Scott (Radnor, PA); Bozena Korczak (Wayne, PA)
Assignee: Innovation Pharmaceuticals Inc.
A61K31/167A61K9/006A61K31/4025A61K31/4178A61K31/505A61K31/506A61K38/18A61K38/1825A61K45/06C07D239/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,603,294
App. No.
16/248,422
Granted
Mar 31, 2020
Kind
B2
Abstract

The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.

Claims (14)

1. A method of treating or preventing mucositis in a human comprising administering an oral, buccal, or sublingual pharmaceutical composition to the human in need thereof, wherein the pharmaceutical composition comprises a compound having the formula

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the pharmaceutical composition is a rinse.

3. The method of claim 1 , wherein the pharmaceutical composition further comprises an analgesic.

4. The method of claim 1 , wherein the pharmaceutical composition further comprises an antibiotic.

5. The method of claim 1 , wherein the pharmaceutical composition further comprises palifermin.

6. The method of claim 1 , wherein the human also receives chemotherapy, radiation therapy, or both, for the treatment of cancer.

7. The method of claim 1 , wherein the human also receives high-dose chemotherapy prior to hematopoietic cell transplantation.

8. The method of claim 1 , wherein the human also receives radiation therapy for a tumor of the head and neck.

9. The method of claim 1 , wherein the human also receives induction therapy for leukemia.

10. The method of claim 1 , wherein the human also receives conditioning regimens for bone marrow transplant.

11. The method of claim 1 , wherein the human is experiencing basal epithelial cell death.

12. The method of claim 1 , wherein the mucositis is ulcerative oral mucositis.

13. The method of claim 1 , wherein the human is experiencing severe oral ulcerations.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2019
From: SCOTT, RICHARD W.; KORCZAK, BOZENA
To: POLYMEDIX, INC.
Reel/Frame 049408/0226 →
BANKRUPTCY COURT ORDER/ASSET PURCHASE AGREEMENT Recorded Jun 7, 2019
From: POLYMEDIX, INC.
To: CELLCEUTIX CORPORATION
Reel/Frame 049412/0052 →
CHANGE OF NAME Recorded Jun 7, 2019
From: CELLCEUTIX CORPORATION
To: INNOVATION PHARMACEUTICALS INC.
Reel/Frame 049413/0176 →
Continuity (7)
Continuation 15702186 · Sep 12, 2017
Continuation 15239460 · Aug 17, 2016
Continuation 14836177 · Aug 26, 2015
Continuation 14456202 · Aug 11, 2014
Continuation 13471689 · May 15, 2012
Provisional Application 61486455 · May 16, 2011
Related Publication 20190282521A1 · Sep 19, 2019